Prelude PF Patellae

K143543 · Biomet, Inc. · KRR · Jan 30, 2015 · Orthopedic

Device Facts

• Record ID: K143543
• Device Name: Prelude PF Patellae
• Applicant: Biomet, Inc.
• Product Code: KRR · Orthopedic
• Decision Date: Jan 30, 2015
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 888.3540
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

The Prelude™ PF Resurfacing Knee System is intended to be used in cemented patellofemoral arthroplasty in patients with degenerative arthritis in the distal femur and patients with a history of patellar dislocation or patella fracture, or patients with failed previous surgery (arthroscopy, tibial tubercle elevation, lateral release) where pain, deformity or dysfunction persists.

Device Story

Prelude PF Patellae are orthopedic prosthetic components designed for cemented patellofemoral arthroplasty. These components serve as larger-sized options for the existing Prelude PF Knee Resurfacing System. Used by orthopedic surgeons in a clinical/surgical setting, the device replaces damaged or dysfunctional patellar surfaces. The components are manufactured from UHMWPE with a stainless steel x-ray wire for radiographic visualization. The device is implanted to restore joint function and alleviate pain associated with degenerative arthritis or prior surgical failure. No software or algorithmic processing is involved.

Clinical Evidence

No clinical data. Substantial equivalence is supported by engineering analysis demonstrating that the additional sizes do not raise new risks compared to the predicate device.

Technological Characteristics

Materials: UHMWPE (ASTM F-648) with stainless steel x-ray wire. Design: Patellar component for cemented patellofemoral arthroplasty. Sterilization: Identical to predicate (single-use).

Indications for Use

Indicated for patients with degenerative arthritis in the distal femur, history of patellar dislocation or fracture, or failed previous surgery (arthroscopy, tibial tubercle elevation, lateral release) experiencing persistent pain, deformity, or dysfunction.

Regulatory Classification

Identification

A knee joint patellofemoral polymer/metal semi-constrained cemented prosthesis is a two-part device intended to be implanted to replace part of a knee joint in the treatment of primary patellofemoral arthritis or chondromalacia. The device limits translation and rotation in one or more planes via the geometry of its articulating surfaces. It has no linkage across-the-joint. This generic type of device includes a component made of alloys, such as cobalt-chromium-molybdenum or austenitic steel, for resurfacing the intercondylar groove (femoral sulcus) on the anterior aspect of the distal femur, and a patellar component made of ultra-high molecular weight polyethylene. This generic type of device is limited to those devices intended for use with bone cement (§ 888.3027). The patellar component is designed to be implanted only with its femoral component.

Special Controls

*Classification.* Class II. The special controls for this device are:(1) FDA's: (i) “Use of International Standard ISO 10993 ‘Biological Evaluation of Medical Devices—Part I: Evaluation and Testing,’ ” (ii) “510(k) Sterility Review Guidance of 2/12/90 (K90-1),” (iii) “Guidance Document for Testing Orthopedic Implants with Modified Metallic Surfaces Apposing Bone or Bone Cement,” (iv) “Guidance Document for the Preparation of Premarket Notification (510(k)) Applications for Orthopedic Devices,” and (v) “Guidance Document for Testing Non-articulating, ‘Mechanically Locked’ Modular Implant Components,” and (2) International Organization for Standardization's (ISO): (i) ISO 5832-3:1996 “Implants for Surgery—Metallic Materials—Part 3: Wrought Titanium 6-Aluminum 4-Vandium Alloy,” (ii) ISO 5832-4:1996 “Implants for Surgery—Metallic Materials—Part 4: Cobalt-Chromium-Molybdenum Casting Alloy,” (iii) ISO 5832-12:1996 “Implants for Surgery—Metallic Materials—Part 12: Wrought Cobalt-Chromium-Molybdenum Alloy,” (iv) ISO 5833:1992 “Implants for Surgery—Acrylic Resin Cements,” (v) ISO 5834-2:1998 “Implants for Surgery—Ultra-high Molecular Weight Polyethylene—Part 2: Moulded Forms,” (vi) ISO 6018:1987 “Orthopaedic Implants—General Requirements for Marking, Packaging, and Labeling,” (vii) ISO 7207-2:1998 “Implants for Surgery—Components for Partial and Total Knee Joint Prostheses—Part 2: Articulating Surfaces Made of Metal, Ceramic and Plastic Materials,” and (viii) ISO 9001:1994 “Quality Systems—Model for Quality Assurance in Design/Development, Production, Installation, and Servicing,” and (3) American Society for Testing and Materials': (i) F 75-92 “Specification for Cast Cobalt-28 Chromium-6 Molybdenum Alloy for Surgical Implant Material,” (ii) F 648-98 “Specification for Ultra-High-Molecular-Weight Polyethylene Powder and Fabricated Form for Surgical Implants,” (iii) F 799-96 “Specification for Cobalt-28 Chromium-6 Molybdenum Alloy Forgings for Surgical Implants,” (iv) F 1044-95 “Test Method for Shear Testing of Porous Metal Coatings,” (v) F 1108-97 “Titanium-6 Aluminum-4 Vanadium Alloy Castings for Surgical Implants,” (vi) F 1147-95 “Test Method for Tension Testing of Porous Metal Coatings,” (vii) F 1537-94 “Specification for Wrought Cobalt-28 Chromium-6 Molybdenum Alloy for Surgical Implants,” and (viii) F 1672-95 “Specification for Resurfacing Patellar Prosthesis.”

Predicate Devices

• Prelude PF Knee Resurfacing System (K123907)
• Vanguard Patella Components (K040770)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo is circular and contains the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. In the center of the circle is an abstract symbol consisting of three stylized human profiles facing to the right, arranged in a stacked formation.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

January 30, 2015

Biomet Incorporated Mr. Jared Cooper Regulatory Affairs Specialist 56 East Bell Drive Warsaw, Indiana 46581

Re: K143543 Trade/Device Name: Prelude PF Patellae Regulation Number: 21 CFR 888.3540 Regulation Name: Knee joint patellofemoral polymer/metal semi-constrained cemented prosthesis Regulatory Class: Class II Product Code: KRR Dated: December 9, 2014 Received: December 15, 2014

Dear Mr. Cooper:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing

{1}------------------------------------------------

## Page 2 - Mr. Jared Cooper

(21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number [phone] or [phone] or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number [phone] or [phone] or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely vours.

Vincent J. Devlin -S for Mark N. Melkerson Director Division of Orthopedic Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

## Indications for Use

510(k) Number (if known)

K143543

Device Name Prelude PF Patellae

Indications for Use (Describe)

The Prelude™ PF Resurfacing Knee System is intended to be used in cemented patellofemoral arthroplasty in patients with degenerative arthritis in the distal femur and patients with a history of patellar dislocation or patella fracture, or patients with failed previous surgery (arthroscopy, tibial tubercle elevation, lateral release) where pain, deformity or dysfunction persists.

Type of Use (Select one or both, as applicable)

| <div> <span style="font-size:10px">☑</span> Prescription Use (Part 21 CFR 801 Subpart D) </div> | <div> <span style="font-size:10px">☐</span> Over-The-Counter Use (21 CFR 801 Subpart C) </div> |
|----------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|
|----------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|

#### CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

#### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff [e-mail]

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

Image /page/3/Picture/0 description: The image shows the word "BIOMET" in a simple, sans-serif font. The letters are all capitalized and evenly spaced. The color of the letters is a dark gray, and the background is white. The overall impression is clean and modern.

# 510(k) Summary

In accordance with 21 CFR §807.92 and the Safe Medical Devices Act of 1990, the following information is provided for the Prelude PF Patellae 510(k) premarket notification. The submission was prepared in accordance with the FDA guidance document, 'Format for Traditional and Abbreviated 510(k)s', issued on August 12, 2005.

| Sponsor: | Biomet Inc.<br>56 East Bell Drive<br>PO Box 587<br>Warsaw, IN 46581<br>Establishment Registration Number: 1825034 |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Contact: | Jared Cooper, PhD<br>Regulatory Affairs Specialist<br>Biomet Sports Medicine<br>Phone: [phone]<br>Fax: [phone] |
| Date: | December 9, 2014 |
| Subject Device: | Trade Name: Prelude PF Patellae<br>Common Name: Unicondylar Knee Prosthesis<br>Classification Name:<br>• KRR- Prosthesis, Knee, Patello/Femoral, Semi-constrained<br>Cemented, metal/polymer (21 CFR §888.3540) |

### Legally marketed devices to which substantial equivalence is claimed:

- K123907 - Prelude PF Knee Resurfacing System
- K040770 - Vanguard Patella Components

#### Device Description

The patella components are to be used with the existing Prelude PF Knee Resurfacing System. The components manufactured from polyethylene (UHMWPE) conforming to ASTM F-648 with a stainless steel x-ray wire and consist of larger sized patella options.

#### Intended Use and Indications for Use

The Prelude™ PF Resurfacing Knee System is intended to be used in cemented patellofemoral arthroplasty in patients with degenerative arthritis in the distal femur and patients with a history of patellar dislocation or patella fracture, or patients with failed previous surgery (arthroscopy, tibial tubercle elevation, lateral release) where pain, deformity or dysfunction persists.

#### Summary of Technological Characteristics

{4}------------------------------------------------

BIOMET

The rationale for substantial equivalence is based on consideration of the following characteristics:

- Intended Use: The proposed and predicate Prelude PF Knee Resurfacing System patellae devices have the identical intended use.
- Indications for Use: The proposed and predicate Prelude PF Knee Resurfacing System patellae devices have identical indications for use.
- Materials: The proposed and predicate Prelude PF Knee Resurfacing System patellae devices are manufactured from UHMWPE conforming to ASTM F648.
- Design Features: The proposed and predicate patellae devices incorporate identical design features.
- Sterilization: The proposed and predicate Prelude PF Knee Resurfacing System patellae devices are provided sterile via identical sterilization methods for single-use.

## Summary of Performance Data (Nonclinical and/or Clinical)

- . Non-Clinical Tests
- o Engineering Analysis of the larger patellae demonstrate that the proposed additional sizes to the Prelude PF Knee Resurfacing System patellae do not raise any new risks compared to the predicate Prelude PF Knee Resurfacing System patellae.
- . Clinical Tests
- o None

## Substantial Equivalence Conclusion

The proposed Prelude PF Knee Resurfacing System patellae have identical intended use, indications for use, and design as the predicate devices. Engineering analysis demonstrates the Prelude PF patellae do not raise any new risks compared to the legally marketed predicate devices.